345 results on '"Bisagni, G"'
Search Results
102. Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
103. Abstract P5-12-05: 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER
104. Abstract P2-17-01: Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First-Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer
105. Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.
106. Preplanned first-step analysis of LET-LOB neoadjuvant study: A double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer
107. Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study
108. 522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy
109. Proliferation and apoptosis before and after primary systemic therapy for operable breast cancer
110. Incidence and risk factors for central nervous system (CNS) metastases in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts)
111. A phase II study of the novel oral camptothecin ST1481 in pretreated metastatic colorectal cancer (CRC)
112. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non-small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc)
113. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole★.
114. Treatment of stage IIIB-IV non small cell lung cancer (NSCLC) with Gemcitabine, Ifosfamide, Cisplatin (GIP). A phase II study
115. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC)
116. P79 Three new highly active cisplatin-containing combinations in locally-advanced (stage III) and locally-recurrent breast carcinoma. A phase II randomized study
117. P86 Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer
118. Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study
119. 721 Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2B (IFN) in advanced colorectal cancer (ACRC): A randomized trial of the italian oncology group for clinical research (GOIRC)
120. M-VAC combination in locally advanced, locally recurrent or metastatic breast carcinoma. A phase II study
121. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
122. Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study.
123. Cisplatin and etoposide in advanced colorectal carcinoma
124. Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
125. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
126. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
127. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.
128. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)
129. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial.
130. 88O Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial.
131. Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies
132. 186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
133. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13-AMBRA Study
134. HER-2 AMPLIFICATION (HER-2+) AND CHROMOSOME 17 POLYSOMY AS PROGNOSTIC FACTORS IN PATIENTS WITH RADICALLY RESECTED NON-SMALL-CELL LUNG CANCER (NSCLC)
135. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial
136. Estrogen Receptors and Breast Cancer: A New Approach to the Cut-off Problem
137. C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients
138. 721 Hydroxyurea (HU), high dose folinic acid (L-FA) and 5FU VS HU, 5FU and interferon-alfa-2B(IFN) in advanced colorectal cancer (ACRC): A randomized trial of the italian oncology group for clinical research (GOIRC)
139. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
140. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
141. 124 (PB-124) Poster - Adjuvant endocrine therapy choices in premenopausal patients with estrogen receptor-positive early breast cancer: insights from the GIM23-POSTER study.
142. 3 Young Investigator Awardee - Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo trials (MIG).
143. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer
144. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
145. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole★.
146. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials
147. Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
148. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)
149. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
150. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.